S-equol is a soy-derived isoflavone metabolite being evaluated in the ACE Trial (Arterial Stiffness, Cognition and Equol), a Phase 2 clinical trial for Alzheimer's disease and vascular cognitive impairment. The trial is sponsored by the University of Pittsburgh under Principal Investigator Akira Sekikawa, MD, PhD, with funding from the National Institute on Aging (NIA grant R01AG074971)[@ace_trial][@sekikawa].
This is a 24-month, multicenter, randomized, double-blind, placebo-controlled trial enrolling 369 participants aged 65-85. The primary outcomes arearterial stiffness measured by pulse wave velocity, white matter lesion (WML) volume on MRI, and cognitive decline measured by the Preclinical Alzheimer's Cognitive Composite-5 (PACC-5)[@ace_trial].
S-equol is a soy-derived isoflavone metabolite being evaluated in the ACE Trial (Arterial Stiffness, Cognition and Equol), a Phase 2 clinical trial for Alzheimer's disease and vascular cognitive impairment. The trial is sponsored by the University of Pittsburgh under Principal Investigator Akira Sekikawa, MD, PhD, with funding from the National Institute on Aging (NIA grant R01AG074971)[@ace_trial][@sekikawa].
This is a 24-month, multicenter, randomized, double-blind, placebo-controlled trial enrolling 369 participants aged 65-85. The primary outcomes arearterial stiffness measured by pulse wave velocity, white matter lesion (WML) volume on MRI, and cognitive decline measured by the Preclinical Alzheimer's Cognitive Composite-5 (PACC-5)[@ace_trial].
Background: The Equol Producer Phenomenon
Equol is a metabolite of soy isoflavone daidzein, transformed by gut bacteria in the microbiome. The key insight driving this trial is the equol producer phenomenon:
East Asian populations: 50-70% of individuals are "equol producers" who can convert daidzein to S-equol
Western populations: Only 20-30% are equol producers
Clinical implication: The Women's Isoflavone Soy Health (WISH) trial in the US showed no significant cognitive benefit from soy isoflavones overall, but subgroup analysis revealed that equol producers had better cognition than non-producers[@Wish]
This suggests that previous null results in soy isoflavone trials may have been confounded by the failure to account for equol-producing status, and that direct S-equol supplementation may bypass the need for gut microbiome conversion.
Mechanism of Action
S-equol is a phytoestrogen with multiple neuroprotective mechanisms[@sekikawa2022]:
Estrogen Receptor-β Agonism
S-equol acts primarily as an agonist of estrogen receptor-β (ER-β or ESR2), which is abundantly expressed in the brain, particularly in regions vulnerable to Alzheimer's pathology:
[ER-β](/genes/esr2) modulates neuronal survival, synaptic plasticity, and neuroinflammation
ER-β activation is neuroprotective in animal models of AD and PD
Unlike estradiol, S-equol does not stimulate estrogen-sensitive tissues, avoiding cancer risks
Antioxidant Activity
S-equol is characterized as "the most potent antioxidant among all known soy isoflavones"[@sekikawa2022]:
Scavenges reactive oxygen species (ROS)
Protects against lipid peroxidation
Reduces oxidative damage to neurons
Blood-Brain Barrier Permeability
S-equol demonstrates superior permeability across the blood-brain barrier compared to parent soy isoflavones (daidzein, genistein):
Directly reaches brain parenchyma
Exerts central nervous system effects
Vascular Protection
The trial targets vascular contributions to cognitive impairment:
Arterial stiffness: Strong predictor of cognitive decline, independently associated with white matter lesions and dementia risk
White matter lesions (WMLs): Small vessel disease in the brain, associated with executive dysfunction and progression to dementia
S-equol has been shown to reduce arterial stiffness in short-term RCTs
ACE Trial Design
ClinicalTrials.gov ID: NCT05741060
Primary Outcomes
Arterial stiffness — Change from baseline at 12 and 24 months, measured by pulse wave velocity (PWV)
White matter lesion volume — Change from baseline at 24 months, measured by MRI
Secondary Outcomes
Cognitive function — PACC-5 score at 12 and 24 months
University of Pittsburgh (Pittsburgh, PA) — Lead site
Wake Forest University (Winston-Salem, NC)
Emory University (Atlanta, GA)
Scientific Rationale
The ACE trial tests the hypothesis that direct S-equol supplementation will:
Reduce arterial stiffness, a modifiable vascular risk factor
Reduce white matter lesion progression
Preserve cognitive function in older adults without dementia
This addresses the vascular contribution to cognitive impairment and dementia (VCID), increasingly recognized as a key target for Alzheimer's prevention.